How Atorvastatin Lowers LDL Cholesterol
Atorvastatin, sold as Lipitor, is a statin that competitively inhibits HMG-CoA reductase, the enzyme that controls the rate-limiting step in hepatic cholesterol biosynthesis: the conversion of HMG-CoA to mevalonate.[1]
This inhibition reduces intracellular cholesterol levels in liver cells. The drop triggers sterol regulatory element-binding protein (SREBP) activation, which upregulates LDL receptor (LDLR) gene expression. More LDL receptors migrate to hepatocyte surfaces, increasing uptake and clearance of circulating LDL cholesterol from the blood via endocytosis.[1][2]
What Happens Upstream and Downstream
Lower hepatic cholesterol also reduces cholesterol esterification and suppresses VLDL production, indirectly cutting LDL precursors. A small direct effect binds and blocks intestinal cholesterol absorption via NPC1L1, though this is minor compared to LDLR upregulation.[2]
Why LDL Drops More Than Total Cholesterol
Atorvastatin preferentially lowers LDL (30-60% reduction at clinical doses) over HDL or triglycerides due to its potency on LDLR induction. High-intensity doses (40-80 mg) achieve greater LDLR expression than low doses.[1][3]
How It Compares to Other Statins
Atorvastatin is more lipophilic than hydrophilic statins like rosuvastatin, allowing better hepatocyte penetration and stronger HMG-CoA inhibition. This yields 1.5-2x greater LDL reduction per mg dose versus simvastatin.[3]
Does It Affect Other Pathways?
Minimal impact on PCSK9 (which degrades LDLR); instead, statins slightly lower PCSK9 via SREBP-2, prolonging LDLR availability. No significant effect on HDL via CETP modulation.[2]
When Does the LDL Effect Kick In
LDL drops 20-30% within 2 weeks, peaking at 4-6 weeks with daily dosing. Steady-state inhibition sustains via its 14-hour half-life.[1]
[1]: DrugPatentWatch.com - Atorvastatin Patent Details
[2]: Nature Reviews Drug Discovery - Statin Mechanisms
[3]: NEJM - Statin Comparative Efficacy